View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, June 27 (HealthDay News) -- Women at risk of placental insufficiency who are treated with unfractionated heparin (UFH) during pregnancy may not have significantly better outcomes than those undergoing standard care, according to a study published online June 20 in the Journal of Thrombosis and Haemostasis.
John C.P. Kingdom, M.D., of the University of Toronto, and colleagues investigated the efficacy of UFH treatment in 32 women at high-risk of placental insufficiency in the second trimester. Thrombophilia screen-negative women, with either false-positive first- or second-semester serum tests or other medical/obstetric risk factors, were randomly allocated to receive 7500 IU UFH twice daily until birth or 34 weeks' gestation (16 women) or standard care. Sonography of the placenta and uterine artery Doppler were performed between 18 and 22 weeks. Maternal-infant outcomes, including maternal anxiety, were evaluated.
The investigators found no statistically major difference between the standard care group and the UFH group in the mean anxiety score, birth weight, perinatal death, severe preeclampsia, placental weight below the 10th percentile, or placental infarction.
"Our study design and findings, including placental pathology data, challenge the widely prevailing view that pregnant women should receive prophylactic heparin to improve perinatal outcomes based solely on clinical risk factors for placental insufficiency," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top